CAS: 34919-98-7; 2-[2-[3-(Tert-Butylamino)-2-Hydroxypropoxy]Phenoxy]-N-Methylacetamide

该化合物是一种化学化合物,属于乙型肾上腺激素抗体,通常称为乙型阻塞器,主要用于治疗高血压和某些心脏病,因为它能够阻塞肾上腺素和无肾上腺素对乙型肾上腺素受体的动作,这导致心率和血压下降. 白蛋白的特征是,它对乙型1型肾上腺受体(主要在心脏中发现)采取相对有选择性的行动,使其有效地管理心血管问题,同时尽量减少与非选择性乙型阻塞体有关的副作用.该化合物通常以口服形式施用,并可能受到各种致癌性功能的影响,包括吸收,新陈代谢和排泄,从而影响其治疗效率和安全情况. 与任何药物一样,潜在的副作用可能包括疲劳,眩晕和胃肠道紊乱,在治疗期间需要谨慎监测.

结构式图片

MSDS等安全信息

    上下游产品

    CAS号4385-48-2 苯并[b][1,4]二氧杂环己... | CAS号34919-78-3 2-(2-hydroxyphe... | CAS号75-64-9 叔丁胺 | CAS号106-89-8 环氧氯丙烷

    合成工艺路线路线简述

      海关参考信息

      专利信息


      专利号:US-10925977-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
      发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
      权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
      摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

      专利号:US-2008287407-A1
      优先权日:2003-12-10
      标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
      发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
      权利人:NITROMED INC
      摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

      专利号:US-7708989-B2
      优先权日:1999-10-29
      标题 :Methods of treating vascular diseases characterized by nitric oxide insufficiency
      发明人:LOSCALZO JOSEPH; VITA JOSEPH A; LOBERG MICHAEL D; WORCEL MANUEL
      权利人:NITROMED INC
      摘要:The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.

      专利号:US-7384976-B2
      优先权日:2001-05-02
      标 题:Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use
      发明人:GARVEY DAVID S
      权利人:NITROMED INC
      摘要:The invention describes novel compositions comprising nebivolol and/or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and/or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and/or preventing Raynaud's syndrome; and for treating and/or preventing cardiovascular diseases or disorders.

      专利号:US-8017776-B2
      优先权日:2003-07-15
      标题 :Methods for synthesis of acyloxyalkyl compounds
      发明人:BHAT LAXMINARAYAN; GALLOP MARK A
      权利人:XENOPORT INC
      摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.

      专利号:US-2008214827-A1
      优先权日:2004-02-03
      标 题:Synthesis of Cyanoimino-Benzoimidazoles
      发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
      权利人:EURO CELTIQUE SA
      摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Beaulieu G, Grimes D, Muirhead C, Oshiro G. Cetamolol: cardiovascular effects of a new cardioselective beta-adrenoceptor blocker possessing partial agonistic activity and lacking membrane-stabilizing activity. Can J Physiol Pharmacol. 1984 Jun;62(6):610-6. doi: 10.1139/y84-098. 28(6):495-504. doi: 10.1002/j.1552-4604.1988.tb03166.x. 62(3):302-8. doi: 10.1139/y84-047. 19(4):411-6. doi: 10.1111/j.1365-2125.1985.tb02663.x.
      5: White WB, Schulman P, McCabe EJ, Hager WD. Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate. Clin Pharmacol Ther. 1986 Jun;39(6):664-8. doi: 10.1038/clpt.1986.116. 12(2):208-17. doi: 10.1097/00005344-198808000-00011. 28(5):467-76. doi: 10.1002/j.1552-4604.1988.tb05762.x. 28(8):751-6. doi: 10.1002/j.1552-4604.1988.tb03210.x. 13(1):118-24. 122(8):857-8.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知